Physician profile
Robert A Luke
NPI 1992707327
$1,140.12
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $643 · 2020: $105 · 2021: $147 · 2023: $125 · 2024: $121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $246.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $246.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $234.08 | 2019-2023 | Watchman Access System |
| Abbott Laboratories | $146.77 | 2021 | |
| Medtronic, INC. | $121.23 | 2024 | Linq II |
| Edwards Lifesciences Corporation | $117.65 | 2019 | |
| Irhythm Technologies, INC. | $108.59 | 2019 | |
| Medtronic Vascular, INC. | $104.55 | 2020 | |
| Janssen Pharmaceuticals, INC | $77.43 | 2019 | |
| Sanofi-Aventis U.S. LLC | $47.40 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $42.60 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.51 | 2019 | |
| Amgen INC. | $31.14 | 2019 | |
| Novartis Pharmaceuticals Corporation | $27.78 | 2019 | |
| Gilead Sciences, INC. | $15.77 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.24 | 2019 | |
| Pfizer INC. | $12.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Luke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.